MCID: MNC007
MIFTS: 59

Monocytic Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 51 14 69
M5b Acute Differentiated Monocytic Leukemia 69
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD10 32 C93.Z C93.Z0 C93
ICD9CM 34 206.8

Summaries for Monocytic Leukemia

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to leukemia, acute monocytic and acute monoblastic leukemia. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mitoxantrone and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, monocytes and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Wikipedia : 72 Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the... more...

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 33.8 CD14 KAT6A KIAA0100 KMT2A
2 acute monoblastic leukemia 31.9 CSF2 CXCL8 IL6 KMT2A
3 hematopoietic stem cell transplantation 29.8 IFNG IL6 TNF
4 langerhans cell histiocytosis 29.5 CSF1 CSF2 IFNG
5 neutrophilia, hereditary 29.4 CSF2 IL6
6 thrombocytosis 29.1 CSF2 F3 IL6
7 graft-versus-host disease 29.1 IFNG IL1B IL6 TNF
8 cytomegalovirus infection 29.0 CXCL8 IFNG IL6 TNF
9 obstructive jaundice 29.0 CXCL8 IL6 TNF
10 myeloma, multiple 28.9 CASP3 CSF2 CXCL8 IL6
11 gingivitis 28.8 CXCL8 IL1B IL6 TNF
12 aplastic anemia 28.8 CSF1 CSF2 IFNG IL6 TNF
13 prostatitis 28.6 CXCL8 IL1B IL6 TNF
14 pertussis 28.4 IL1B IL6 ITGAM JUN TNF
15 respiratory failure 28.1 CXCL8 F3 TNF
16 leukemia, acute myeloid 27.0 CASP3 CSF1 CSF2 F3 IFNG ITGAM
17 adult acute monocytic leukemia 12.4
18 aleukemic monocytic leukemia cutis 12.3
19 chronic monocytic leukemia 12.2
20 subacute monocytic leukemia 12.2
21 leukemia 10.9
22 scorpion envenomation 10.3 IL6 TNF
23 polyposis, gastric 10.3 IL1B TNF
24 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
25 critical limb ischemia 10.2 IL6 TNF
26 autoimmune myocarditis 10.2 IFNG PPARG TNF
27 chronic mucocutaneous candidiasis 10.2 CSF1 IFNG IL6
28 microscopic colitis 10.2 IFNG IL6 TNF
29 intermediate uveitis 10.2 IFNG IL6 TNF
30 systemic onset juvenile idiopathic arthritis 10.2 IL1B TNF
31 plasmodium vivax malaria 10.2 IFNG IL6 TNF
32 rasmussen encephalitis 10.2 IFNG IL6 TNF
33 ascaris lumbricoides infection 10.2 IFNG IL1B IL6
34 paracoccidioidomycosis 10.2 IFNG IL6 TNF
35 mixed connective tissue disease 10.1 IFNG IL6 TNF
36 echinococcosis 10.1 IFNG IL6 TNF
37 melioidosis 10.1 IFNG IL6 TNF
38 reactive arthritis 10.1 IFNG IL6 TNF
39 human immunodeficiency virus infectious disease 10.1 IFNG IL6 TNF
40 campylobacteriosis 10.1 IFNG IL1B JUN
41 spondyloarthropathy 10.1 IFNG IL6 TNF
42 parasitic protozoa infectious disease 10.1 IFNG IL6 TNF
43 laryngitis 10.1 IL1B IL6 TNF
44 filariasis 10.1 IFNG IL6 TNF
45 acute vascular insufficiency of intestine 10.1 IL1B IL6 TNF
46 staphylococcal toxic shock syndrome 10.1 IFNG IL1B TNF
47 poems syndrome 10.1 IL1B IL6 TNF
48 burning mouth syndrome 10.1 IL1B IL6 TNF
49 osteosclerotic myeloma 10.1 IL1B IL6 TNF
50 multicentric castleman disease 10.1 F3 IFNG IL6

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

43 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 TNF PPARG CSF1 CASP3 CSF2 CD14
2 cardiovascular system MP:0005385 10.37 KMT2A TNF PPARG CSF1 CASP3 CSF2
3 homeostasis/metabolism MP:0005376 10.37 KMT2A TNF PPARG CSF1 CASP3 CD14
4 cellular MP:0005384 10.36 KMT2A TNF PPARG CSF2 CSF1 CASP3
5 growth/size/body region MP:0005378 10.36 KMT2A TNF PPARG CSF2 CSF1 CASP3
6 immune system MP:0005387 10.36 TNF PPARG CSF1 CASP3 CSF2 CD14
7 behavior/neurological MP:0005386 10.34 PPARG KMT2A TNF CSF1 CASP3 CSF2
8 integument MP:0010771 10.27 TNF PPARG CSF1 CASP3 CSF2 F3
9 mortality/aging MP:0010768 10.27 PPARG KMT2A TNF CD14 CSF1 CASP3
10 endocrine/exocrine gland MP:0005379 10.21 PPARG TNF CSF1 CASP3 CSF2 IFNG
11 craniofacial MP:0005382 10.18 KMT2A TNF CSF2 CSF1 CASP3 IFNG
12 nervous system MP:0003631 10.18 KMT2A TNF PPARG CSF1 CASP3 CSF2
13 embryo MP:0005380 10.17 PPARG KMT2A TNF CSF2 IFNG F3
14 liver/biliary system MP:0005370 10.08 KMT2A TNF PPARG CSF1 IFNG JUN
15 muscle MP:0005369 10.03 PPARG KMT2A TNF CSF1 CASP3 IFNG
16 neoplasm MP:0002006 10.01 KMT2A TNF PPARG CSF2 IFNG F3
17 reproductive system MP:0005389 9.91 PPARG KMT2A TNF CSF1 CASP3 CSF2
18 no phenotypic analysis MP:0003012 9.87 PPARG KMT2A TNF CSF1 CASP3 IFNG
19 respiratory system MP:0005388 9.81 TNF CSF1 CASP3 CD14 CSF2 IFNG
20 skeleton MP:0005390 9.73 TNF PPARG CSF1 CASP3 CSF2 CD14
21 vision/eye MP:0005391 9.23 PPARG TNF CSF1 CASP3 IFNG F3

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
2
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
3
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
4
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
5
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
6
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
9
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
12
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
13
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
14
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
16
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
17
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 460612 4053
18
Hydroxyurea Approved Phase 3 127-07-1 3657
19
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
21
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
22
Asparaginase Approved, Investigational Phase 3,Phase 2,Phase 1 9015-68-3
23
Carmustine Approved, Investigational Phase 3 154-93-8 2578
24
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
25
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
26
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
27
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
28
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
29
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
30
Cyproheptadine Approved Phase 3 129-03-3 2913
31
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
32
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
34
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
35 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
36
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
37 Analgesics Phase 3,Phase 2,Phase 1
38 Alkylating Agents Phase 3,Phase 2,Phase 1
39 Gemtuzumab Phase 2, Phase 3, Phase 1
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
41 Vaccines Phase 3,Phase 1
42 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
43 Dermatologic Agents Phase 3,Phase 2,Phase 1
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Antibodies, Monoclonal Phase 3,Phase 2
46 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anti-HIV Agents Phase 3,Phase 1,Phase 2
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antifungal Agents Phase 3,Phase 2,Phase 1,Early Phase 1
50 Immunoglobulins Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 186)

# Name Status NCT ID Phase Drugs
1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
6 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
11 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
12 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
13 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
14 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
15 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
16 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
17 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
18 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
19 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
20 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
21 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
22 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
23 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
24 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
25 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
26 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
27 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
28 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
29 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
30 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
33 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
34 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
37 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
38 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
39 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
40 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
41 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
42 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Completed NCT01168219 Phase 2 Azacitidine;Busulfan;Fludarabine Phosphate;Methotrexate;Tacrolimus
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
44 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
46 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
47 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
48 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

38
Myeloid, Monocytes, Bone, Bone Marrow, Skin, Lung, Prostate

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 532)
# Title Authors Year
1
Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells. ( 29435054 )
2018
2
Anti-Cancerous Effect of Inonotus taiwanensis Polysaccharide Extract on Human Acute Monocytic Leukemia Cells through ROS-Independent Intrinsic Mitochondrial Pathway. ( 29382173 )
2018
3
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
4
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
5
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
6
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
7
5a89azaa892'a89deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2a89CCR2a89ERK signaling pathway. ( 28627644 )
2017
8
C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia. ( 28693135 )
2017
9
5-Aminoimidazole-4-carboxamide ribonucleoside-induced autophagy flux during differentiation of monocytic leukemia cells. ( 28975042 )
2017
10
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
11
Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. ( 29156705 )
2017
12
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
13
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. ( 27859216 )
2017
14
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
15
Treatment-related acute granulocyte-monocytic leukemia from multiple myeloma: A case report and literature review. ( 29390389 )
2017
16
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
17
The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-I_B Signaling. ( 28832545 )
2017
18
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
19
Antioxidation and antiproliferation of ethanol extracts from edible mushrooms against U937 human monocytic leukemia cells. ( 27976050 )
2016
20
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
21
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
22
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
23
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
24
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
25
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
26
A Wnt pathway activator induces apoptosis and cell death in mouse monocytic leukemia cells. ( 27623760 )
2016
27
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
28
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
29
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
30
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
31
Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. ( 25546124 )
2015
32
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
33
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
34
Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. ( 26582014 )
2015
35
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
36
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2015
37
Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells. ( 26134921 )
2015
38
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
39
Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplant in patients with chronic myelo-monocytic leukemia (CMML) ? ( 26576835 )
2015
40
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
41
Modulation of monocytic leukemia cell function and survival by high gradient magnetic fields and mathematical modeling studies. ( 24439412 )
2014
42
Severe aplastic anemia preceding acute monocytic leukemia in an adult with acquired trisomy 21: A case report. ( 24396488 )
2014
43
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
44
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
45
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014
46
Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. ( 24503697 )
2014
47
RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. ( 24652966 )
2014
48
Regulated cellular exposure to non-thermal plasma allows preferentially directed apoptosis in acute monocytic leukemia cells. ( 23400198 )
2013
49
Reverse signaling from LIGHT promotes pro-inflammatory responses in the human monocytic leukemia cell line, THP-1. ( 24044961 )
2013
50
Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study. ( 24179516 )
2013

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
2
Show member pathways
13.91 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
3
Show member pathways
13.75 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
4
Show member pathways
13.49 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
5
Show member pathways
13.47 CASP3 CSF1 CSF2 CXCL8 IFNG IL1B
6
Show member pathways
13.41 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
7
Show member pathways
13.16 CASP3 CD14 CSF2 IL6 ITGAM JUN
8
Show member pathways
13.08 CD14 CXCL8 F3 IL1B IL6 JUN
9
Show member pathways
12.95 CASP3 CXCL8 IFNG IL1B IL6 TNF
10 12.93 CASP3 CXCL8 IFNG IL6 JUN PPARG
11
Show member pathways
12.92 CASP3 CXCL8 IFNG IL1B IL6 JUN
12 12.87 CASP3 CD14 CSF1 IL1B JUN TNF
13
Show member pathways
12.79 CXCL8 IFNG IL1B IL6 TNF
14
Show member pathways
12.75 CASP3 IFNG IL1B JUN TNF
15
Show member pathways
12.7 CASP3 CSF2 CXCL8 IL6 JUN TNF
16
Show member pathways
12.69 CASP3 CD14 IL1B JUN TNF
17
Show member pathways
12.68 IFNG IL1B IL6 JUN TNF
18
Show member pathways
12.68 CD14 IFNG IL1B IL6 TNF
19
Show member pathways
12.67 CD14 CXCL8 IFNG IL1B IL6 JUN
20
Show member pathways
12.62 CASP3 CSF2 IFNG JUN TNF
21
Show member pathways
12.56 CSF2 IFNG IL1B IL6 JUN TNF
22 12.47 CSF2 IL6 JUN TNF
23
Show member pathways
12.47 CASP3 CSF2 CXCL8 IFNG IL1B IL6
24
Show member pathways
12.45 CSF1 IFNG IL1B IL6 TNF
25
Show member pathways
12.41 CD14 CXCL8 IFNG IL1B IL6 JUN
26
Show member pathways
12.4 CASP3 IFNG IL1B ITGAM JUN TNF
27 12.4 CD14 CSF2 CXCL8 IL6 ITGAM KMT2A
28
Show member pathways
12.39 CD14 CXCL8 IL6 JUN TNF
30 12.37 CASP3 CD14 IFNG IL1B IL6 ITGAM
31 12.33 CASP3 CXCL8 IL1B IL6 JUN TNF
32
Show member pathways
12.32 CD14 CXCL8 IFNG IL1B IL6 JUN
33
Show member pathways
12.29 CXCL8 IFNG IL1B IL6 TNF
34 12.27 CASP3 IFNG IL6 TNF
35 12.21 CSF1 IFNG IL1B JUN PPARG TNF
36 12.19 IFNG IL1B JUN TNF
37 12.17 CASP3 CXCL8 IFNG IL1B IL6 TNF
38 12.16 CD14 CSF1 CSF2 IFNG IL6 ITGAM
39 12.13 CXCL8 IL1B IL6 ITGAM TNF
40 12.09 CXCL8 IFNG IL1B IL6 JUN KMT2A
41 12.09 CASP3 CSF1 CSF2 IL1B IL6 JUN
42
Show member pathways
12.08 IFNG IL1B IL6 JUN TNF
43 12.03 CASP3 CXCL8 F3 IL1B IL6 JUN
44 12.01 CD14 IL6 ITGAM PPARG
45 12.01 CD14 CSF1 CSF2 IL1B IL6 ITGAM
46 12 CD14 CXCL8 IL1B TNF
47
Show member pathways
11.99 CD14 CSF2 CXCL8 IL6
48 11.96 CSF2 CXCL8 IFNG IL6 JUN
49 11.94 CD14 CSF2 CXCL8 IFNG IL1B IL6
50 11.92 IFNG IL1B ITGAM TNF

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CD14 CSF1 CSF2 CXCL8 F3 IFNG
2 extracellular space GO:0005615 9.32 CD14 CSF1 CSF2 CXCL8 F3 IFNG
3 MOZ/MORF histone acetyltransferase complex GO:0070776 9.16 KAT6A KAT6B

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 CXCL8 IL1B IL6 JUN KMT2A PPARG
2 response to lipopolysaccharide GO:0032496 9.94 CASP3 CD14 IL1B JUN
3 inflammatory response GO:0006954 9.93 CD14 CSF1 CXCL8 IL1B IL6 TNF
4 positive regulation of gene expression GO:0010628 9.91 CSF1 CSF2 IFNG IL1B IL6 TNF
5 negative regulation of transcription, DNA-templated GO:0045892 9.87 CSF2 IFNG JUN KAT6A KAT6B PPARG
6 positive regulation of DNA binding transcription factor activity GO:0051091 9.86 IL1B IL6 PPARG TNF
7 cellular response to organic cyclic compound GO:0071407 9.85 CASP3 IL1B TNF
8 apoptotic signaling pathway GO:0097190 9.85 CASP3 CD14 TNF
9 regulation of insulin secretion GO:0050796 9.84 IFNG IL1B TNF
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 CSF2 IFNG IL6
11 response to glucocorticoid GO:0051384 9.83 CASP3 IL6 TNF
12 response to organic substance GO:0010033 9.83 CASP3 JUN PPARG TNF
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 IL6 JUN TNF
14 humoral immune response GO:0006959 9.82 IFNG IL6 TNF
15 positive regulation of interleukin-6 production GO:0032755 9.79 IL1B IL6 TNF
16 positive regulation of interferon-gamma production GO:0032729 9.78 CD14 IL1B TNF
17 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.78 CASP3 F3 PPARG TNF
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 IFNG IL1B TNF
19 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.76 CSF2 IL1B TNF
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.75 CD14 IL1B TNF
21 regulation of receptor activity GO:0010469 9.7 CSF1 CSF2 CXCL8 IFNG IL1B IL6
22 negative regulation of collagen biosynthetic process GO:0032966 9.69 IL6 PPARG
23 response to molecule of bacterial origin GO:0002237 9.69 CD14 CXCL8
24 positive regulation of podosome assembly GO:0071803 9.68 CSF2 TNF
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 IL1B TNF
26 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
27 positive regulation of monocyte differentiation GO:0045657 9.67 CSF1 JUN
28 positive regulation of osteoclast differentiation GO:0045672 9.67 CSF1 IFNG TNF
29 positive regulation of chemokine biosynthetic process GO:0045080 9.66 IL1B TNF
30 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
31 cellular response to lipopolysaccharide GO:0071222 9.65 CD14 CSF2 CXCL8 IL6 TNF
32 positive regulation of interleukin-23 production GO:0032747 9.63 CSF2 IFNG
33 positive regulation of fever generation GO:0031622 9.62 IL1B TNF
34 sequestering of triglyceride GO:0030730 9.59 IL1B TNF
35 monocyte differentiation GO:0030224 9.58 CSF2 JUN PPARG
36 positive regulation of transcription, DNA-templated GO:0045893 9.56 IL1B IL6 JUN KAT6A KAT6B KMT2A
37 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 IFNG TNF
38 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.54 IFNG IL1B TNF
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 8.8 IFNG IL1B TNF
40 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 IL1B IL6 JUN KAT6B KMT2A PPARG
41 positive regulation of cell proliferation GO:0008284 10.04 CSF1 CSF2 IFNG IL1B IL6 JUN
42 immune response GO:0006955 10.02 CSF2 CXCL8 IFNG IL1B IL6 TNF
43 positive regulation of apoptotic process GO:0043065 10.01 CASP3 IL6 JUN PPARG TNF

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 CASP3 CD14 CSF1 CSF2 CXCL8 F3
2 transcription regulatory region DNA binding GO:0044212 9.46 JUN KMT2A PPARG TNF
3 acetyltransferase activity GO:0016407 9.26 KAT6A KAT6B
4 cytokine activity GO:0005125 9.17 CSF1 CSF2 CXCL8 IFNG IL1B IL6

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....